Literature DB >> 12147681

The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor.

Elias A Said1, Bernard Krust, Sébastien Nisole, Josette Svab, Jean-Paul Briand, Ara G Hovanessian.   

Abstract

The growth factor midkine (MK) is a cytokine that inhibits the attachment of human immunodeficiency virus particles by a mechanism similar to the nucleolin binding HB-19 pseudopeptide. Here we show that the binding of MK to cells occurs specifically at a high and a low affinity binding site. HB-19 prevents the binding of MK to the low affinity binding site only. Confocal immunofluorescence laser microscopy revealed the colocalization of MK and the cell-surface-expressed nucleolin at distinct spots. The use of various deletion constructs of nucleolin then indicated that the extreme C-terminal end of nucleolin, containing repeats of the amino acid motif RGG, is the domain that binds MK. The specific binding of MK to cells is independent of heparan sulfate and chondroitin sulfate expression. After binding to cells, MK enters cells by an active process. Interestingly, the cross-linking of surface-bound MK with a specific antibody results in the clustering of surface nucleolin along with glycosylphosphatidylinositol-linked proteins CD90 and CD59, thus, pointing out that MK binding induces lateral assemblies of nucleolin with specific membrane components of lipid rafts. Our results suggest that the cell surface-expressed nucleolin serves as a low affinity receptor for MK and could be implicated in its entry process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12147681     DOI: 10.1074/jbc.M201194200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Cell surface nucleolin on developing muscle is a potential ligand for the axonal receptor protein tyrosine phosphatase-sigma.

Authors:  Daniel E Alete; Mark E Weeks; Ara G Hovanession; Muhamed Hawadle; Andrew W Stoker
Journal:  FEBS J       Date:  2006-09-21       Impact factor: 5.542

Review 2.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

Review 3.  Midkine in host defence.

Authors:  A Gela; S Jovic; S L Nordin; A Egesten
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells.

Authors:  Santanu Bose; Mausumi Basu; Amiya K Banerjee
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

5.  Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation.

Authors:  Cheng Xu; Yunfei Wang; Qiu Tu; Zhiye Zhang; Mengrou Chen; James Mwangi; Yaxiong Li; Yang Jin; Xudong Zhao; Ren Lai
Journal:  Oncogene       Date:  2018-10-24       Impact factor: 9.867

6.  Induction of fibroblast apolipoprotein E expression during apoptosis, starvation-induced growth arrest and mitosis.

Authors:  Carmel M Quinn; Katarina Kågedal; Alexei Terman; Uri Stroikin; Ulf T Brunk; Wendy Jessup; Brett Garner
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

7.  Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice.

Authors:  Diala El Khoury; Damien Destouches; Renée Lengagne; Bernard Krust; Yamina Hamma-Kourbali; Marylène Garcette; Sandra Niro; Masashi Kato; Jean-Paul Briand; José Courty; Ara G Hovanessian; Armelle Prévost-Blondel
Journal:  BMC Cancer       Date:  2010-06-24       Impact factor: 4.430

8.  Structure-function analysis of nucleolin and ErbB receptors interactions.

Authors:  Keren Farin; Ayelet Di Segni; Adam Mor; Ronit Pinkas-Kramarski
Journal:  PLoS One       Date:  2009-07-03       Impact factor: 3.240

9.  Identification of the RGG box motif in Shadoo: RNA-binding and signaling roles?

Authors:  Susan M Corley; Jill E Gready
Journal:  Bioinform Biol Insights       Date:  2008-11-19

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.